MedTrace Logo

Exploratory Study to Assess the Pharmacokinetics of AZD5985

NCT00799331 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2009-06-09

No results posted yet for this study

Summary

The aim of this exploratory study is to assess the pharmacokinetics of increasing oral doses of AZD5985 in healthy male volunteers

Conditions

  • Healthy

Interventions

DRUG

AZD5985

Oral suspension. Single oral doses of AZD5985 starting with 4 mg and subsequently with up to 3 dose escalations will be administered not exceeding AstraZeneca pre-defined upper exposure limits.

DRUG

placebo

Oral suspension.

Sponsors & Collaborators

Principal Investigators

  • Eva Pettersson · AstraZeneca R&D, Lund, Sweden

  • Maura Fallon · Parexel, Berlin, Germany

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2009-02-28
Completion
2009-02-28

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00799331 on ClinicalTrials.gov